These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 29197742)

  • 1. Asparaginase inhibits the lectin pathway of complement activation.
    Keizer MP; Aarts C; Kamp AM; Caron HN; van de Wetering MD; Wouters D; Kuijpers TW
    Mol Immunol; 2018 Jan; 93():189-192. PubMed ID: 29197742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Drug Monitoring of Asparaginase: Intra-individual Variability and Predictivity in Children With Acute Lymphoblastic Leukemia Treated With PEG-Asparaginase in the AIEOP-BFM Acute Lymphoblastic Leukemia 2009 Study.
    Würthwein G; Lanvers-Kaminsky C; Gerss J; Möricke A; Zimmermann M; Stary J; Smisek P; Attarbaschi A; Nath C; Zucchetti M; Rizzari C; Schrappe M; Boos J;
    Ther Drug Monit; 2020 Jun; 42(3):435-444. PubMed ID: 32022785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
    Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
    Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).
    Jarrar M; Gaynon PS; Periclou AP; Fu C; Harris RE; Stram D; Altman A; Bostrom B; Breneman J; Steele D; Trigg M; Zipf T; Avramis VI
    Pediatr Blood Cancer; 2006 Aug; 47(2):141-6. PubMed ID: 16425271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin and alternative pathways of complement.
    Nielsen EW; Waage C; Fure H; Brekke OL; Sfyroera G; Lambris JD; Mollnes TE
    Mol Immunol; 2007 Mar; 44(8):1819-26. PubMed ID: 17101176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The synergism of 6-mercaptopurine plus cytosine arabinoside followed by PEG-asparaginase in human leukemia cell lines (CCRF/CEM/0 and (CCRF/CEM/ara-C/7A) is due to increased cellular apoptosis.
    Nandy P; Periclou AP; Avramis VI
    Anticancer Res; 1998; 18(2A):727-37. PubMed ID: 9615712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia.
    Wenner KA; Vieira Pinheiro JP; Escherich G; Wessalowski R; Jorch N; Wolff J; Stehn M; Kohlschütter A; Boos J; Janka-Schaub GE
    Klin Padiatr; 2005; 217(6):321-6. PubMed ID: 16307417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process.
    Hamad I; Hunter AC; Szebeni J; Moghimi SM
    Mol Immunol; 2008 Dec; 46(2):225-32. PubMed ID: 18849076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-Asparaginase lowers plasma antithrombin and mannan-binding-lectin levels: Impact on thrombotic and infectious events in children with acute lymphoblastic leukemia.
    Merlen C; Bonnefoy A; Wagner E; Dedeken L; Leclerc JM; Laverdière C; Rivard GE
    Pediatr Blood Cancer; 2015 Aug; 62(8):1381-7. PubMed ID: 25820776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients.
    Armstrong JK; Hempel G; Koling S; Chan LS; Fisher T; Meiselman HJ; Garratty G
    Cancer; 2007 Jul; 110(1):103-11. PubMed ID: 17516438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Structural Basis for Complement Inhibition by Gigastasin, a Protease Inhibitor from the Giant Amazon Leech.
    Pang SS; Wijeyewickrema LC; Hor L; Tan S; Lameignere E; Conway EM; Blom AM; Mohlin FC; Liu X; Payne RJ; Whisstock JC; Pike RN
    J Immunol; 2017 Dec; 199(11):3883-3891. PubMed ID: 29061764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia.
    Avramis VI; Tiwari PN
    Int J Nanomedicine; 2006; 1(3):241-54. PubMed ID: 17717965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase.
    Asselin BL; Ryan D; Frantz CN; Bernal SD; Leavitt P; Sallan SE; Cohen HJ
    Cancer Res; 1989 Aug; 49(15):4363-8. PubMed ID: 2743326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL.
    Appel IM; Pinheiro JP; den Boer ML; Lanvers C; Reniers NC; Boos J; Pieters R
    Leukemia; 2003 Nov; 17(11):2254-6. PubMed ID: 14523472
    [No Abstract]   [Full Text] [Related]  

  • 15. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97.
    Vieira Pinheiro JP; Wenner K; Escherich G; Lanvers-Kaminsky C; Würthwein G; Janka-Schaub G; Boos J
    Pediatr Blood Cancer; 2006 Jan; 46(1):18-25. PubMed ID: 15929133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peg-asparaginase for acute lymphoblastic leukemia.
    Rytting M
    Expert Opin Biol Ther; 2010 May; 10(5):833-9. PubMed ID: 20345338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TFPI inhibits lectin pathway of complement activation by direct interaction with MASP-2.
    Keizer MP; Pouw RB; Kamp AM; Patiwael S; Marsman G; Hart MH; Zeerleder S; Kuijpers TW; Wouters D
    Eur J Immunol; 2015 Feb; 45(2):544-50. PubMed ID: 25359215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of the lectin pathway of complement by cardiopulmonary bypass contributes to the development of systemic inflammatory response syndrome after paediatric cardiac surgery.
    Pągowska-Klimek I; Świerzko AS; Michalski M; Głowacka E; Szala-Poździej A; Sokołowska A; Moll M; Krajewski WR; Romak J; Cedzyński M
    Clin Exp Immunol; 2016 May; 184(2):257-63. PubMed ID: 26703090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood acute lymphoblastic leukemia.
    Bushman JE; Palmieri D; Whinna HC; Church FC
    Leuk Res; 2000 Jul; 24(7):559-65. PubMed ID: 10867129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel site-specific PEGylated L-asparaginase.
    Meneguetti GP; Santos JHPM; Obreque KMT; Barbosa CMV; Monteiro G; Farsky SHP; Marim de Oliveira A; Angeli CB; Palmisano G; Ventura SPM; Pessoa-Junior A; de Oliveira Rangel-Yagui C
    PLoS One; 2019; 14(2):e0211951. PubMed ID: 30753228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.